Tuberculosis drug discovery: an in-house toxin blocks pathogenic bacterial growth
Tuberculosis causes more deaths worldwide every year than any other infectious disease, except COVID-19. Today, its treatment is getting increasingly challenging due to the rise of antibiotic-resistant variants of disease-causing bacteria. We discovered an in-house toxin that blocks pathogenic bacterial growth, offering potential clues for future drug design.
Infectious diseases rank among the greatest threats to human health. While the world stumbles through the current COVID-19 pandemic, a vast array of viral, fungal, parasitic, and bacterial pathogens continue to threaten people's lives. Before the rise of the pandemic, tuberculosis was the world's deadliest infectious disease, killing around 1.5 million people per year with 1.7 billion global infections.
Tuberculosis is caused by the pathogenic bacteria Mycobacterium tuberculosis (Mtb). The bacteria spreads among humans by aerosol droplets and primarily infects the respiratory system. Tuberculosis is curable. However, its treatment is getting increasingly challenging due to the rise of antibiotic-resistant Mtb variants, which can survive existing drug treatments. These bacterial variants can exploit "tools" to tolerate external stresses such as those from antibiotics. Extending our understanding of these anti-stress tools will help develop more targeted and effective drugs.
Toxin-antitoxin systems are one such bacterial anti-stress tool. These systems consist of a toxic molecule (toxin) and its antidote molecule (antitoxin), both of which are naturally present within bacterial cells. But why would bacteria produce a toxin that may expose themselves to danger? The antitoxin is the trick — it can specifically associate with the toxin to inactivate its function, fitting together like pieces of a jigsaw puzzle. Under normal conditions, the toxin remains inactive and harmless as it is neutralized by the antitoxin. However, under certain conditions, the toxin becomes free to target essential cellular processes, which eventually stalls bacterial growth and likely puts them into a dormant state that is stress-tolerant. This suggests that if such a system is found in the disease-causing bacteria, we may be able to block their growth by selectively disrupting the toxin-antitoxin balance.
In this study, we investigated a new family of possible toxin-antitoxin systems in the pathogenic bacteria Mtb. Firstly, we asked whether these systems are indeed functional. To our delight, we found that a toxin called MenT3, the strongest in the family, was able to stop bacterial growth. This stalling of bacterial growth was restored by its antitoxin MenA3. We thus discovered a new functional toxin-antitoxin system in the Mtb bacteria, which can potentially help them tolerate stress.
To better understand how the MenT3 toxin molecularly behaves to inhibit Mtb bacterial growth, we uncovered its 3D structure. This allowed us to identify other molecules structurally similar to MenT3: those involved in a cellular process called protein biosynthesis. Proteins are molecular machinery essential for life, and therefore their biosynthesis is indispensable. Finding the structural resemblance prompted us to hypothesize that MenT3 might stop bacterial growth by interfering with this core biological process. As protein biosynthesis is a complex process in which many different components are involved, we set out to identify which molecule the MenT3 toxin specifically targets. We found that MenT3 interacted with molecules called transfer RNAs — known as key actors in protein biosynthesis. Indeed, this molecular interaction allowed MenT3 to switch off transfer RNA's function by altering its structure.
Overall, we revealed how the in-house toxin MenT3 blocks the growth of the tuberculosis-causing bacteria by interfering with protein biosynthesis. While it is still unknown whether the MenT3-MenA3 toxin-antitoxin system contributes to bacterial infection and stress tolerance, we expect that future studies will answer these questions. If the MenT3-MenA3 system is indeed important for infection in humans, it could present a potential new drug target. This study puts a milestone in developing a new strategy to treat this severe infectious disease.
Cai, Y. et al. A nucleotidyltransferase toxin inhibits growth of Mycobacterium tuberculosis through inactivation of tRNA acceptor stems. Sci. Adv. 6, (2020).
Next read: Symbiogenesis: how algae and bacteria shaped new genes together by Raphaël Méheust , Eric Bapteste
Dr. Akira Ohkubo , Associate Editor
We thought you might like
How humans gave acne to the grapevineFeb 28, 2015 in Evolution & Behaviour | 3.5 min read by Carlos J. Rivera-Rivera
Tara Oceans Expedition sequences the oceanNov 24, 2015 in Earth & Space | 4 min read by Chris Bowler
Living without mitochondria: the downfall of one textbook truthOct 3, 2016 in Evolution & Behaviour | 3.5 min read by Lukáš Novák
Amoebas trap bacteria using nets of DNA: the same mechanism as human immune cellsJan 27, 2017 in Evolution & Behaviour | 3.5 min read by Lukáš Novák
More from Microbiology
How cellular transport can be explained with a flip bookJun 5, 2023 in Microbiology | 3 min read by Christina Elsner
The Achilles’ heel of superbugs that survive salty dry conditionsApr 24, 2023 in Microbiology | 4 min read by Heng Keat Tam
New chemistry in unusual bacteria displays drug-like activityMar 21, 2023 in Microbiology | 3.5 min read by Grace Dekoker , Joshua Blodgett
Unlocking a new way to fight against antibiotic resistance: viruses are the keyJun 8, 2022 in Microbiology | 4 min read by Fernando L. Gordillo Altamirano , Jeremy J. Barr
Blocking protein folding to fight antibiotic resistanceMay 13, 2022 in Microbiology | 4 min read by R. Christopher D. Furniss , Nikol Kaderabkova , Despoina A.I. Mavridou